Cerdelga (eliglustat) — United Healthcare

Initial criteria

• Diagnosis of Gaucher disease type 1
• AND
• Patient is one of the following as detected by an FDA-cleared test:
• (1) CYP2D6 extensive metabolizer
• (2) CYP2D6 intermediate metabolizer
• (3) CYP2D6 poor metabolizer

Reauthorization criteria

• Documentation of positive clinical response to Cerdelga therapy

Approval duration

12 months